Janusz Milanowski

Janusz Milanowski is a Professor and Chair of the Department of Pneumology, Oncology and Allergology at the Faculty of Medicine, Medical University of Lublin. He is an active academic physician and researcher with a strong focus on lung cancer, immunotherapy, and respiratory diseases. His work bridges clinical practice and molecular research, particularly in non-small cell and small cell lung cancer.

His research interests center on oncology, pulmonary medicine, and allergology, with a strong emphasis on immunotherapy efficacy, biomarker discovery, genetic mutations (e.g., KRAS, ALK, BRAF), and liquid biopsy applications. He also investigates the impact of environmental factors such as air pollution and occupational exposures on respiratory health and cancer outcomes.

The most recent publications reflect a consistent trend in advancing personalized treatment strategies for lung cancer patients. His work explores predictive biomarkers including NLR, PLR, gut microbiome, and microRNAs, aiming to optimize immunotherapy outcomes. There is a strong focus on real-world clinical evidence, molecular subtyping, and overcoming resistance in targeted therapies.

While specific scientific awards are not listed in the provided text, his leadership as a department chair and high publication output in reputable journals indicate significant recognition in his field.

Prof. Milanowski supervises research theses and collaborates extensively with a multidisciplinary team, particularly with researchers like Paweł Krawczyk, Anna Grenda, and Natalia Galant. His work is supported by institutional infrastructure and includes participation in clinical and translational research projects. He also contributes to understanding immune responses in broader contexts, including SARS-CoV-2 exposure in healthcare workers.

His laboratory or research team appears to focus on translational lung cancer research, integrating clinical data, molecular profiling, and microbiome analysis to improve patient outcomes. The work is highly collaborative and spans both oncology and immunology domains.